Cytokine pathways and joint inflammation in rheumatoid arthritis.
Choy
E H
EH
Department of Rheumatology, Guy's, King's, and St. Thomas' Hospitals School of Medicine, King's College, London, United Kingdom.
Panayi
G S
GS
D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D018501:Antirheumatic Agents / Q000627:therapeutic use; D001172:Arthritis, Rheumatoid / Q000188:drug therapy* / Q000276:immunology*; D016207:Cytokines / Q000037:antagonists & inhibitors* / Q000378:metabolism / Q000502:physiology* / Q000627:therapeutic use; D000068800:Etanercept; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007249:Inflammation / Q000276:immunology; D000069285:Infliximab; D018121:Receptors, Cytokine / Q000037:antagonists & inhibitors; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D015398:Signal Transduction
D000911:Antibodies, Monoclonal; D018501:Antirheumatic Agents; D016207:Cytokines; D007074:Immunoglobulin G; D018121:Receptors, Cytokine; D018124:Receptors, Tumor Necrosis Factor; D000069285:Infliximab; D000068800:Etanercept